What SpIntellx does

SpIntellx, operating commercially as PredxBio, Inc., is a Pittsburgh-based spatial tissue intelligence company founded in 2017 that builds decision-support software for pharmaceutical and biotechnology drug development teams. Its core product, the SpaceIQ platform, ingests complex spatial multi-omic tissue data — including functional cell states, spatial microenvironments, and cell-cell interactions — and applies machine learning, image processing, and computational biology algorithms to surface response-defining tissue patterns. The platform is structured around three interconnected modules: Discovery & Mechanism Intelligence (target and mechanism-of-action support), Translational & Clinical Readiness (biomarker and patient stratification), and Trial & Program-Scale Decision Support (trial design, inclusion criteria refinement, go/no-go decisions).

The company is led by CEO B. Dusty Majumdar, PhD (formerly of GE Healthcare, Exact Sciences, and 3M), Sr. VP Business Development Joe Camaratta (former GE Healthcare and Siemens Healthcare executive), and VP Software Engineering Bruce Campbell, MS (former IBM Global Director of Data Science with 20+ years shipping FDA 510(k)-cleared and CLIA-certified digital pathology algorithms). IP basis includes multiple filed patents held by Dr. Majumdar.

Commercial motion is enterprise field sales targeting pharma and biotech R&D decision-makers, supported by content marketing (whitepapers, newsletter), direct engagement CTAs, and an event-led demand generation layer anchored by the proprietary Spatial Intelligence Summit (Pittsburgh, annually) and major conference presence (AACR 2026: six posters, Booth #1723). Revenue mechanics appear to be enterprise subscription or platform licensing with quote-based pricing, though commercial terms are not publicly disclosed. Cumulative disclosed funding is approximately $1.67M across nine rounds (2018-2023) from Innovation Works, Keiretsu Capital, AlphaLab Health, Newlin Investment Company, and a National Science Foundation SBIR award, supporting a small 1-10 person team operating from 100 S Jackson Avenue, Pittsburgh, PA.

Name

SpIntellx

Legal name

PredxBio, Inc.

Website

https://spintellx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

SpIntellx (operating as PredxBio) is a Pittsburgh-based spatial tissue intelligence company whose SpaceIQ platform applies machine learning to spatial multi-omic data to support drug development decisions for pharmaceutical and biotechnology R&D teams.

Ownership category

akta.pro rank

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Software Platform/SaaS: SpaceIQ platform appears to be offered as a software solution to pharmaceutical and biotech companies for tissue intelligence analysis. Revenue likely derives from platform licensing or subscription, though specific commercial terms are not disclosed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SpIntellx (operating through PredxBio, Inc.) develops and sells the SpaceIQ decision-intelligence platform, which transforms complex tissue and multi-omic spatial data into explainable insights for pharmaceutical and biotech drug development teams. The platform supports discovery and mechanism intelligence, translational and clinical biomarker development, and trial-scale decision support through machine learning, image processing, and computational biology algorithms.

Product overview

PredxBio offers a single unified platform called SpaceIQ™ that provides decision-grade tissue intelligence for drug development. The platform operates across three interconnected phases: Discovery & Mechanism Intelligence (reveals response-defining tissue biology to inform target selection and mechanism-of-action hypotheses), Translational & Clinical Readiness (defines predictive tissue-based biomarkers and patient stratification based on tissue-level biology linked to therapeutic response), and Trial & Program-Scale Decision Support (applies consistent, reproducible tissue intelligence across studies to guide trial strategy and enable learning to compound across programs). The platform processes spatial multi-omic data to uncover response-driving biology that conventional analyses miss.

Differentiator

Problem solved

Functional benefit

Brands

• SpaceIQ: Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights for drug development - from early discovery through clinical programs and portfolio strategy.

Products and services

• SpaceIQ Platform Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights that guide drug development — from early discovery through clinical programs and portfolio strategy. It is sold to pharmaceutical and biotech drug development teams and operates through three interconnected capabilities: Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• Crohn's & Colitis FoundationminorGTM or Marketing PartnerJoe Camaratta serves as an advisor to the Entrepreneurial Investing Program of the Crohn's & Colitis Foundation, indicating a minor advisory/marketing partnership relationship.
• University Science Center QED ProgramminorStrategic or Co-development PartnerJoe Camaratta serves as an advisor to the University Science Center QED Program focused on commercialization of academic innovations, indicating a minor strategic advisory relationship.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/33271742
• Xx.com/spintellx
• Facebookfacebook.com/SpIntellx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpIntellx